scholarly journals Novel Action of the Chalcone Isoliquiritigenin as a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitor: Potential Therapy for Cholera and Polycystic Kidney Disease

2012 ◽  
Vol 118 (1) ◽  
pp. 82-91 ◽  
Author(s):  
Chatchai Muanprasat ◽  
Lalida Sirianant ◽  
Sunhapas Soodvilai ◽  
Ratchanaporn Chokchaisiri ◽  
Apichart Suksamrarn ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Transmembrane Conductance Regulator ◽  
Polycystic Kidney ◽  
Transmembrane Conductance ◽  
Cystic Fibrosis Transmembrane

scholarly journals CF Gene and Cystic Fibrosis Transmembrane Conductance Regulator Expression in Autosomal Dominant Polycystic Kidney Disease

2000 ◽  
Vol 11 (12) ◽  
pp. 2285-2296
Author(s):  
ALEXANDRE PERSU ◽  
OLIVIER DEVUYST ◽  
NATHALIE LANNOY ◽  
ROLAND MATERNE ◽  
GODELA BROSNAHAN ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Kidney Disease ◽  
Autosomal Dominant ◽  
Transmembrane Conductance Regulator ◽  
Polycystic Kidney ◽  
Transmembrane Conductance ◽  
Δf508 Cftr ◽  
Autosomal Dominant Polycystic Kidney ◽  
And Control ◽  
Renal Phenotype

Abstract. Disease-modifying genes might participate in the significant intrafamilial variability of the renal phenotype in autosomal dominant polycystic kidney disease (ADPKD). Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is a chloride channel that promotes intracystic fluid secretion, and thus cyst progression, in ADPKD. The hypothesis that mutations of the CF gene, which encodes CFTR, might be associated with a milder renal phenotype in ADPKD was tested. A series of 117 unrelated ADPKD probands and 136 unaffected control subjects were screened for the 12 most common mutations and the frequency of the alleles of the intron 8 polymorphic Tn locus of CF. The prevalence of CF mutations was not significantly different in the ADPKD (1.7%, n = 2) and control (3.7%, n = 5) groups. The CF mutation was ΔF508 in all cases, except for one control subject (1717-1G A). The frequencies of the 5T, 7T, and 9T intron 8 alleles were also similar in the ADPKD and control groups. Two additional patients with ADPKD and the ΔF508 mutation were detected in the families of the two probands with CF mutations. Kidney volumes and renal function levels were similar for these four patients with ADPKD and ΔF508 CFTR (heterozygous for three and homozygous for one) and for control patients with ADPKD collected in the University of Colorado Health Sciences Center database. The absence of a renal protective effect of the homozygous ΔF508 mutation might be related to the lack of a renal phenotype in CF and the variable, tissue-specific expression of ΔF508 CFTR. Immunohistochemical analysis of a kidney from the patient with ADPKD who was homozygous for the ΔF508 mutation substantiated that hypothesis, because CFTR expression was detected in 75% of cysts (compared with <50% in control ADPKD kidneys) and at least partly in the apical membrane area of cyst-lining cells. These data do not exclude a potential protective role of some CFTR mutations in ADPKD but suggest that it might be related to the nature of the mutation and renal expression of the mutated CFTR.

Sign in / Sign up

Export Citation Format

Share Document